top of page

Racial-Ethnic Disparities of Buprenorphine and Vivitrol Receipt in Medicaid

  • Jul 8, 2022
  • 1 min read

key takeaway: "Non-Hispanic Black people, non-Hispanic American Indian or Alaskan Native/Asian/Hawaiian/Pacific Islander people, and Hispanic people had 42%, 12%, and 22% lower odds of buprenorphine receipt and 47%, 12%, and 20% lower odds of Vivitrol receipt, respectively, than non-Hispanic White people, controlling for clinical and demographic patient variables."

Recent Posts

See All
Cannabis and Mental Health: A Review

Cannabis and Mental Health: A Review , in JAMA Internal Medicine key takeaway: "The current evidence base is not sufficient to support the use of cannabis for the treatment of mental health conditions

 
 
 

Comments

bottom of page